Prosecution Insights
Last updated: July 17, 2026
Application No. 18/905,416

MEDICAL ELASTIC SHEET AND MEDICAL DEVICE USING THE SAME

Non-Final OA §103
Filed
Oct 03, 2024
Priority
Oct 05, 2023 — JP 2023-173380
Examiner
JOHANAS, JACQUELINE T
Art Unit
3773
Tech Center
3700 — Mechanical Engineering & Manufacturing
Assignee
Hakko Co. Ltd.
OA Round
2 (Non-Final)
64%
Grant Probability
Moderate
2-3
OA Rounds
1y 1m
Est. Remaining
94%
With Interview

Examiner Intelligence

Grants 64% of resolved cases
64%
Career Allowance Rate
353 granted / 555 resolved
-6.4% vs TC avg
Strong +30% interview lift
Without
With
+30.2%
Interview Lift
resolved cases with interview
Typical timeline
2y 11m
Avg Prosecution
29 currently pending
Career history
586
Total Applications
across all art units

Statute-Specific Performance

§101
0.4%
-39.6% vs TC avg
§103
72.3%
+32.3% vs TC avg
§102
17.7%
-22.3% vs TC avg
§112
8.4%
-31.6% vs TC avg
Black line = Tech Center average estimate • Based on career data from 555 resolved cases

Office Action

§103
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. Claim(s) 1-5, 7 is/are rejected under 35 U.S.C. 103 as being unpatentable over Albrecht et al. (US Publication No. 2011/0054260 A1) in view of Sedic (US Publication No. 2016/0038334 A1). Regarding Claim 1, Albrecht discloses a wound retractor made from a flexible tubular sheath/sheet (150) (fig. 1A). Albrecht discloses that embodiments of the sheath can include rip-stop capabilities in order to resist tear propagation in the event of damage thereto [0060]. However, Albrecht is silent to the sheet comprising rib portions extending from at least one surface of the base portion, wherein the base portion comprises a plurality of cell regions that are each surrounded on an entire circumference by the rib portions and are continuously formed in plane through the rib portions, wherein the rib portions are continuously connected to each other, and wherein the rib portions and the base portion are a solid single sheet integrally molded from elastic material. Sedic discloses a sheath material with rip-stop capabilities in the analogous art of elastic sheet molded medical devices. Sedic discloses the material comprises a sheet-like base portion (104); and rib portions (textured pattern 108) extending from at least one surface of the base portion (“the pattern can be ridges … formed on an inner or outer surface of the device 100. “ [0021]), wherein the base portion comprises a plurality of cell regions (shape 204 shown in Fig. 2) that are each surrounded on an entire circumference by the rib portions and are continuously formed in plane through the rib portions (ridges “formed on an inner/outer surface of the device” in [0021] is disclosure of the material (i.e. rest of device) otherwise being present for the ridges to be disposed on, therefore meeting this limitation), wherein the rib portions are continuously connected to each other (Fig. 4-5), and wherein the rib portions and the base portion are a solid single sheet integrally molded from elastic material [0022]. Sedic discloses that the cell regions provide a rip-stop capability ([0005], claim 24). It would have been obvious to one having ordinary skill in the art before the effective filing date of the claimed invention to modify the sheath of Albrecht to be molded with rib portions in a textured pattern as taught by Sedic in order to provide rip-stop capabilities to contain a tear in the event of damage thereto. Regarding Claim 2-3, Sedic discloses the cell region comprises a polygonal, shape [0026, Sedic] and a hexagonal shape (claim 2, Fig 4-5, [0033] Sedic) . Regarding Claim 4, Sedic discloses the base portion and the rib portions are formed from a same resin material [0022, Sedic]. Regarding Claim 5, the base portion is formed in a tubular shape and the rib portions are formed on at least one of outer and inner surfaces of the tubular base portion (As modified in the rejection of claim 1, the material of the tubular sheath of Albrecht is modified to have molded textured pattern in the form of raised ridges formed on an inner or outer surface of the base portion as taught by Sedic in [0021]. Albrecht already has the base portion /sheath formed in a tubular shape.) Regarding Claim 7, Albrecht in view of Sedic discloses the medical device (wound retractor) as described in claims 1-5 above. The wound retractor comprises annular outer and inner rings (110, 130, Albrecht Fig. 1A) arranged coaxially opposite each other, and the elastic sheet according to claim 5 with both end portions being fixed to the outer and inner rings (Fig. 1A Albrecht). Claim(s) 9-16 is/are rejected under 35 U.S.C. 103 as being unpatentable over Albrecht et al. (US Publication No. 2011/0054260 A1) in view of Sedic (US Publication No. 2016/0038334 A1). Albrecht in view of Sedic discloses the sheet as described in the rejection of claim 1 above. Sedic discloses that the lines forming the texture pattern which provides the rip stop function can have different thickness or widths, different lengths, different height (for ridges) [0024, Sedic]. However, the references are silent to: the rib portions have a height of 0.3 mm to 1 mm; the rib portions have a width of 0.7 mm to 2 mm; or the cell regions have diameter of 2.5 mm to 10 mm. However, it would have been obvious to make the rib portions in the dimensional range of 0.3-1mm (height) or 0.7-2mm (width) because material thickness has a direct and predictable correlation to pliability and strength (the thicker a material zone is, the stronger it is and the less pliable it is) and one of ordinary skill in the art would be able to, through routine experimentation, to discover the optimum or workable ranges of the rib portions to provide the strength for desired tear propagation resistance. It would have also been obvious to optimize the cell region diameter to be within 2.5 mm to 10 mm because this is a direct correlation to how far a tear is capable of propagating. One of ordinary skill would be able to, through routine experimentation, to discover the optimum or workable ranges of the cell diameter to provide the acceptable travel of a potential tear before intersecting a rib. Claim(s) 6 and 8, 11-12 is/are rejected under 35 U.S.C. 103 as being unpatentable over Albrecht et al. (US Publication No. 2011/0054260 A1) in view of Sedic (US Publication No. 2016/0038334 A1) in further view of Jaworek et al. (US Publication No. 2013/0085339 A1). Regarding Claims 6 and 8, Albrecht in view of Sedic discloses the sheet as described in the rejection of claim 1 above. Albrecht discloses the membrane material for providing a wall of a wound retractor, however is silent to the base portion is formed in a flat shape and being a component of a medical device comprising: an annular ring, and the elastic sheet with a peripheral end portion being fixed to the ring. Jaworek discloses a wound retractor in the same field of endeavor comprising an annular ring (102) fixed to a flexible membrane (104) in a flat configuration at the perimeter thereof (Fig. 1B) for providing a barrier to retain organs and tissues from a surgical site [0033]. It would have been obvious to one having ordinary skill in the art to use the membrane material of Albrecht in view of Sedic in a flat configuration attached to an annular ring as taught by Jaworek in order to retract/provide a material suitable as a barrier to retain organs and tissues for a surgical site. Regarding Claims 11-12, Albrecht in view of Sedic discloses the sheet as described in the rejection of claim 1 above. Sedic discloses that the lines forming the texture pattern which provides the rip stop function can have different thickness or widths, different lengths, different height (for ridges) [0024, Sedic]. However, the references are silent to the base portion has a thickness of 0.3 mm to 1 mm. Jaworek discloses a wound retractor in the same field of endeavor comprising a flexible membrane (104) for holding back tissue. Jaworek discloses that the thickness of the membrane is preferable about 1-5 mm thick but other dimensions can be used [0040]. It would have been obvious to make the membrane of Albrecht in view of Sedic to be 1mm thick as taught by Jaworek in order to provide a suitable dimension of a tissue retracting membrane. Further, it would have been obvious to make the membrane in the dimensional range of 0.3-1mm because membrane thickness has a direct and predictable correlation to pliability and strength (the thicker an elastic membrane is, the stronger it is and the less pliable it is) and one of ordinary skill in the art would be able to, through routine experimentation, to discover the optimum or workable ranges of 0.3-1mm of a membrane thickness. Response to Arguments Applicant’s arguments with respect to claim(s) 1-17 have been considered but are moot because the new ground of rejection does not rely on any reference applied in the prior rejection of record for any teaching or matter specifically challenged in the argument. Allowable Subject Matter Claim 17 is objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims. Conclusion The prior art made of record and not relied upon is considered pertinent to applicant's disclosure. See PTO-892 Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to JACQUELINE T JOHANAS whose telephone number is (571)270-5085. The examiner can normally be reached Mon. - Fri. 9:00-5:00. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Eduardo Robert can be reached at 571-272-4719. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /JACQUELINE T JOHANAS/ Primary Patent Examiner, Art Unit 3773
Read full office action

Prosecution Timeline

Oct 03, 2024
Application Filed
Sep 24, 2025
Non-Final Rejection mailed — §103
Nov 18, 2025
Examiner Interview Summary
Dec 22, 2025
Response Filed
Apr 30, 2026
Final Rejection mailed — §103
Jun 30, 2026
Response after Non-Final Action

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12678198
Mechanisms for Strut Length Measurement
1y 5m to grant Granted Jul 14, 2026
Patent 12661130
DEVICE FOR INTRAMEDULLARY NAILING OF THE TIBIA
2y 5m to grant Granted Jun 23, 2026
Patent 12653584
VERTEBRAL IMPLANT FOR DYNAMIC STABILIZATION
2y 3m to grant Granted Jun 16, 2026
Patent 12636042
AUGMENTED REALITY (AR)-ASSISTED ENHANCED FRACTURE REDUCTION FIXATOR
1y 5m to grant Granted May 26, 2026
Patent 12611235
INTRAMEDULLARY NAIL WITH AUTOMATIC DYNAMIZATION AND CONTINUOUS COMPRESSION
2y 2m to grant Granted Apr 28, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

2-3
Expected OA Rounds
64%
Grant Probability
94%
With Interview (+30.2%)
2y 11m (~1y 1m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 555 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month